Read by QxMD icon Read


Dennis Matthews, George C Camba, Ignacio Pascual-Pascual, Ann H Tilton, Mark Gormley, Adnan Mahmood, Philippe Picaut, Daniel Snyder, Mauricio R Delgado
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
Jorge Jacinto, Jovita Balcaitiene, Pascal Maisonobe, Klemens Fheodoroff, Stephen Ashford, Lynne Turner-Stokes
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
Christina Marciniak, Fatma Gul, Ziyad Ayyoub, David M Simpson, Heather W Walker, Michael Wimmer, Claire Vilain, Jean-Michel Graciès
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
Cynthia L Comella, George C Camba, Daniel Truong, Alberto J Espay, Daniel Snyder, Dominic Marchese, Richard Trosch
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
Fatma Gul, Michael O'Dell, Robert Jech, Marta Banach, Claire Vilain, Anne-Sophie As Grandoulier, Jean-Michel Germain, Jean-Michel Graciès
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
Jean-Michel Gracies, Alberto Esquenazi, Allison Brashear, Steven R Edgley, Michael O'Dell, Peter Hedera, Bruce S Rubin, Philippe Picaut
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
Mark F Lew, George C Camba, Daniel Snyder
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
Khashayar Dashtipour, George C Camba, Jack J Chen, Heather W Walker, Michael Y Lee
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
Rungsima Wanitphakdeedecha, Chanida Ungaksornpairote, Arisa Kaewkes, Viboon Rojanavanich, Weeranut Phothong, Woraphong Manuskiatti
BACKGROUND: Botulinum toxin type A (BTA) has been approved for the treatment of strabismus, blepharospasm, muscle spasm, cervical dystonia, pain syndrome, glabella wrinkles, and severe primary axillary hyperhidrosis. Intradermal injection of BTA has been used off-label by many clinicians for the purpose of face-lifting effect. Few studies on onabotulinumtoxinA (ONA) demonstrated no clinical efficacy on face-lifting effect when comparing to normal saline solution (NSS). So far, there is no split-face comparison study on face-lifting effect of abobotulinumtoxinA (ABO)...
September 19, 2016: Journal of Cosmetic Dermatology
Jason D Bloom, Jeremy B Green, Whitney Bowe, Erika von Grote, Alessandra Nogueira
The proportion of men seeking facial rejuvenation with botulinum neurotoxin type A (BoNTA) products is increasing. The number of male patients treated in the 5-year period between 2009 and 2014 grew by 25%. There is little clinical data supporting gender-specific efficacy with regard to dosing and injection placement in men. To nurture the confidence associated with treatment of male patients, clinicians are in need of more informational materials to develop their evaluation and treatment strategies. Three BoNTA products are currently available in the United States (US) for treatment of the upper face...
September 1, 2016: Journal of Drugs in Dermatology: JDD
Michele Poliziani, Marco Koch, Xierong Liu
BACKGROUND: The recommended reinjection interval for botulinum neurotoxin (BoNT) formulations in the treatment of cervical dystonia (CD) is generally ≥12 weeks, though intervals ≥10 weeks are approved for incobotulinumtoxinA in Europe. However, recurring symptoms can occur before the end of this period. Using qualitative research, we sought a greater understanding of disease burden, unmet patient needs, and barriers to treatment. METHODS: We conducted online semistructured, focus-group discussions, and online forum follow-up discussions among patients with CD, focusing on disease burden, patient needs, injection cycle preferences, and relationships with health care professionals...
2016: Patient Preference and Adherence
Gloria Tapias, Mar García-Romero, Carlos Crespo, Maribel Cuesta, Carles Forné, Samuel Ignacio Pascual-Pascual
OBJECTIVE: Cost-minimization analysis of onabotulinumtoxinA and abobotulinumtoxinA, taking into account the real dose administered to children with spasticity associated with dynamic equinus foot deformity due to cerebral palsy. METHOD: A single centre, observational, longitudinal, and retrospective study which included spastic paediatric patients aged 2-to-18-years and treated with onabotulinumtoxinA or abobotulinumtoxinA from December 1995 to October 2012, in the Paediatric Neurology Unit of a first-level Spanish hospital...
September 2016: Farmacia Hospitalaria
John Fezza, John Burns, Julie Woodward, Daniel Truong, Thomas Hedges, Amit Verma
To characterize satisfaction with current standard-of-care botulinum neurotoxin type A (BoNT/A) treatment for blepharospasm, we performed a cross-sectional, structured survey in subjects with blepharospasm who had received ≥2 BoNT/A cycles. Subjects were interviewed immediately before re-injection to evaluate treatment satisfaction, time course of treatment effects, preferred injection intervals, Jankovic Rating Scale (JRS), and Blepharospasm Disability Index (BSDI). Subjects' (n=114) last treatment was onabotulinumtoxinA (n=78), incobotulinumtoxinA (n=35), or abobotulinumtoxinA (n=1)...
August 15, 2016: Journal of the Neurological Sciences
Anna Rostedt Punga, Mohammad Alimohammadi, Dan Fagrell, Frida Nyberg, Diane Rees, Cindy Wong
BACKGROUND: Different volumes of 0.9% NaCl may be used to reconstitute abobotulinumtoxinA yielding an injection volume that ranges from 0.05 to 0.1 mL per injection point for treatment of glabellar lines. OBJECTIVE: To evaluate the efficacy, safety, and subject satisfaction of 2 different injection volumes to deliver the same unit dose of abobotulinumtoxinA for treatment of glabellar lines. MATERIALS AND METHODS: This randomized comparative study was conducted using 2 different reconstitution volumes to deliver a fixed unit dose of 10 Speywood units (sU) of abobotulinumtoxinA in either 0...
August 2016: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
Michael S Gart, Karol A Gutowski
Botulinum toxin type A (BTA) can be used for facial aesthetics. The 3 currently available BTA types include onabotulinumtoxinA (Botox; Botox Cosmetic, Allergan, Irvine, CA), abobotulinumtoxinA (Dysport; Ipsen, Ltd, Berkshire, UK), and incobotulinumtoxinA (Xeomin; Merz Pharmaceuticals, Frankfurt, Germany). The mechanism of action and clinical uses for treatment of dynamic lines of the forehead, brow, glabella, lateral orbit, nose, and lips are presented, as well as treatment of masseter hypertrophy, platysmal bands, and improvements of the perioral region...
July 2016: Clinics in Plastic Surgery
Anna Kutschenko, Anja Manig, Marie-Christine Reinert, Angelika Mönnich, David Liebetanz
Three botulinum neurotoxin type A (BoNT/A) products, incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA, all manufactured by different methods, are employed in clinical practice. Comparing the three BoNT/A products is difficult because their concentrations and volumes differ and the precise dose equivalence ratio is not known. We aimed to compare the neurotoxic potencies by a systematic analysis of injected volume and dose. The potency of BoNT in inducing hind limb paresis was assessed by analyzing the wheel-running performance of mice...
August 3, 2016: Neuroscience Letters
David M Simpson, Mark Hallett, Eric J Ashman, Cynthia L Comella, Mark W Green, Gary S Gronseth, Melissa J Armstrong, David Gloss, Sonja Potrebic, Joseph Jankovic, Barbara P Karp, Markus Naumann, Yuen T So, Stuart A Yablon
OBJECTIVE: To update the 2008 American Academy of Neurology (AAN) guidelines regarding botulinum neurotoxin for blepharospasm, cervical dystonia (CD), headache, and adult spasticity. METHODS: We searched the literature for relevant articles and classified them using 2004 AAN criteria. RESULTS AND RECOMMENDATIONS: Blepharospasm: OnabotulinumtoxinA (onaBoNT-A) and incobotulinumtoxinA (incoBoNT-A) are probably effective and should be considered (Level B)...
May 10, 2016: Neurology
Anthony J Wilson, Brian Chang, Anthony J Taglienti, Bianca C Chin, Catherine S Chang, Nancy Folsom, Ivona Percec
BACKGROUND: U.S. Food and Drug Administration-approved formulations of botulinum toxin include onabotulinumtoxinA (Botox; Allergan, Inc., Irvine, Calif.), abobotulinumtoxinA (Dysport; Galderma Pharma S.A., Lausanne, Switzerland), and incobotulinumtoxinA (Xeomin; Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany). This study uses digital image correlation to compare dynamic strain reduction between available neurotoxins. METHODS: Seventy-three treatment-naive female patients aged were randomized to injection with onabotulinumtoxinA (20 units), abobotulinumtoxinA (60 units), or incobotulinumtoxinA (20 units) in the glabella...
May 2016: Plastic and Reconstructive Surgery
Khashayar Dashtipour, Jack J Chen, Alberto J Espay, Zoltan Mari, William Ondo
OBJECTIVE: This systematic review was performed to elucidate dosing practices, dosing conversions, and related outcomes from randomized controlled trials that directly compared onabotulinumtoxinA (ONA) and abobotulinumtoxinA (ABO) at various dose conversion ratios for therapeutic use in movement disorders. METHODS: A systematic review of 3 medical literature databases (PubMed, the Cochrane Library, and EMBASE) was performed to identify relevant comparative clinical studies, systematic reviews, and meta-analyses published in the English language between January 1991 and January 2015...
March 2016: Movement Disorders Clinical Practice
Alessandro Picelli, Marco Bacciga, Camilla Melotti, Elisabetta LA Marchina, Elisabetta Verzini, Federico Ferrari, Angelo Pontillo, Jessica Corradi, Stefano Tamburin, Leopold Saltuari, Claudio Corradini, Andreas Waldner, Nicola Smania
BACKGROUND: Despite the growing evidence about the use of robotic gait training in neurorehabilitation, there is a scant literature about the combined effects of this innovative technological approach and a first-line treatment for focal spasticity as botulinum toxin type A. In particular, to the best of our knowledge, no previous study evaluated if robotic gait training may enhance the antispastic effect of botulinum toxin type A. AIM: To evaluate the combined effects of robot-assisted gait training and botulinum toxin type A on spastic equinus foot in patients with chronic stroke...
April 21, 2016: European Journal of Physical and Rehabilitation Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"